Aligos Therapeutics Q2 net loss narrows on licensing revenue

Aligos Therapeutics

06/08/2026 13:19

Overview
US biotech firm's Q2 net loss narrowed sharply from prior year
Q2 revenue included $25 mln upfront and $3 mln milestone payments from licensing deals
Operating expenses rose due to increased R&D spending on clinical trials

Outlook
Company expects topline data from Phase 2 B-SUPREME study in late Q3 2027
Aligos expects cash and equivalents to fund operations through Q4 2026
Company expects to receive $3M milestone payment in Q3 2026

Result Drivers
LICENSING PAYMENTS - Q2 revenue driven by $25 mln upfront and $3 mln milestone payments from licensing deals
R&D SPENDING - Operating expenses rose due to increased third-party costs for pevifoscorvir sodium Phase 2 clinical trial

Company press release: ID:nGNX78LWlB

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$0.14
 
Q2 Net Loss
 
$1.50 mln
 
Q2 Income From Operations
 
-$1.89 mln
 
Q2 Operating Expenses
 
$29.67 mln
 
Q2 Pretax Profit
 
$1.31 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Aligos Therapeutics, Inc. is $45.00, about 849.4% above its August 5 closing price of $4.74

Reuters Recommended Reads
Aug 5 - Biopharma firm Xencor's Q2 revenue beats on royalty revenue, milestone payments
Aug 6 - Novavax lifts annual revenue forecast as licensing bets offset weak vaccine demand
Aug 5 - Arcus Biosciences Q2 revenue falls sharply on lower license income

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)